Pérez-Sayáns Mario, Chamorro-Petronacci Cintia M, Baltazar Fátima, Pires Fabio Ramoa, Ínsua Ángel, Suárez-Quintanilla Juan A, Suárez-Peñaranda José M
Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Diagnostics (Basel). 2021 Mar 24;11(4):583. doi: 10.3390/diagnostics11040583.
The aim was to investigate the clinical significance of nestin immunohistochemical expression in head and neck area lesions and to study its role in patient survival and recurrence.
39 (44.3%) nasosinus, 37 (42%) major salivary gland (6 submandibular and 31 parotid) and 12 (13.6%) oral cavity lesions of paraffin-embedded samples were retrospectively included.
The expression was categorized into grades, negative for 55 (62.5%) cases, grade 1 in 10 cases (11.4%), grade 2 in 12 cases (13.6%), and grade 3 in 11 cases (12.5%); 100% of pleomorphic adenomas were positive for nestin with grade 3 intensity, 100% of polyps and inverted papillomas were negative ( < 0.001). The lowest estimate of disease-free-survival (DFS) was for grade 1 expression, with 50 months, confidence interval (CI): 95% 13.3-23.9 months and the highest for grade 3 expression, 167.9 months (CI: 95% 32.1-105 months; Log-Rank = 14.846, = 0.002). ROC (receiver operating characteristic) curves revealed that the positivity for nestin (+/-) in relation to malignancy, presented a sensitivity of 50.98%, a specificity of 81.08%, with an area under the curve of 0.667 ( = 0.009).
Nestin could be a useful marker to detect the presence of stem cells in head and neck tumors that have a role in tumor initiation and progression.
目的是研究巢蛋白免疫组化表达在头颈部病变中的临床意义，并探讨其在患者生存和复发中的作用。
回顾性纳入39例（44.3%）鼻窦、37例（42%）大唾液腺（6例下颌下腺和31例腮腺）以及12例（13.6%）口腔病变的石蜡包埋样本。
表达分为不同等级，55例（62.5%）为阴性，10例（11.4%）为1级，12例（13.6%）为2级，11例（12.5%）为3级；100%的多形性腺瘤巢蛋白呈3级强度阳性，100%的息肉和内翻性乳头状瘤为阴性（<0.001）。无病生存期（DFS）估计最低的是1级表达，为50个月，置信区间（CI）：95% 为13.3 - 23.9个月，最高的是3级表达，为167.9个月（CI：95% 为32.1 - 105个月；对数秩检验 = 14.846，P = 0.002）。ROC（受试者工作特征）曲线显示，巢蛋白（+/-）与恶性肿瘤相关的阳性率，敏感性为50.98%，特异性为81.08%，曲线下面积为0.667（P = 0.009）。
巢蛋白可能是检测头颈部肿瘤中干细胞存在的有用标志物，这些干细胞在肿瘤的发生和发展中起作用。
